- Home
- CBC vs LEGN Comparison
CBC vs LEGN Comparison
Compare CBC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBC | LEGN |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBC | LEGN |
|---|---|---|
| Price | $26.69 | $27.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $28.67 | ★ $61.33 |
| AVG Volume (30 Days) | 522.1K | ★ 2.9M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.15 | $42.68 |
| Revenue Next Year | $6.34 | $30.52 |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.50 | $16.24 |
| 52 Week High | $27.81 | $45.30 |
Technical Indicators
Market Signals| Indicator | CBC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 59.72 |
| Support Level | $23.28 | $25.71 |
| Resistance Level | N/A | $29.69 |
| Average True Range (ATR) | 0.63 | 2.10 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 48.02 | 61.17 |
Price Performance
Historical ComparisonAbout CBC Central Bancompany Inc.
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.